The absent prognostic relevance of FNTB polymorphisms in hormone receptor-positive breast cancer patients could possibly be explained by the fact that RAS signalling, for which the activity of farnesyltransferase is rate-limiting, has a rather subordinate role in this type of breast cancer. This evidence concerns the gene FNTB and breast carcinoma.